ID   DRB5_HUMAN              Reviewed;         266 AA.
AC   Q30154; B2RBV6; C7C4X3; O00157; O00283; O46700; Q29703; Q29787; Q29788;
AC   Q30126; Q30150; Q30199; Q6SJR2; Q7M2H9; Q8HWS7; Q8WLR5; Q9MY54; Q9XRX6;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JAN-2026, entry version 203.
DE   RecName: Full=HLA class II histocompatibility antigen, DR beta 5 chain;
DE   AltName: Full=DR beta-5;
DE   AltName: Full=DR2-beta-2;
DE   AltName: Full=Dw2;
DE   AltName: Full=MHC class II antigen DRB5;
DE   Flags: Precursor;
GN   Name=HLA-DRB5 {ECO:0000312|EMBL:CAI18079.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|PIR:D25239}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS SER-28 AND ALA-154.
RX   PubMed=3099214; DOI=10.1038/324676a0;
RA   Wu S., Saunders T.L., Bach F.H.;
RT   "Polymorphism of human Ia antigens generated by reciprocal intergenic
RT   exchange between two DR beta loci.";
RL   Nature 324:676-679(1986).
RN   [2] {ECO:0000305, ECO:0000312|PIR:C32526}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-28.
RX   PubMed=3571980;
RA   Wu S.K., Yabe T., Madden M., Saunders T.L., Bach F.H.;
RT   "cDNA cloning and sequencing reveals that the electrophoretically constant
RT   DR beta 2 molecules, as well as the variable DR beta 1 molecules, from HLA-
RT   DR2 subtypes have different amino acid sequences including a hypervariable
RT   region for a functionally important epitope.";
RL   J. Immunol. 138:2953-2959(1987).
RN   [3] {ECO:0000312|EMBL:AAA59822.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE DRB5*01:01).
RX   PubMed=3259543; DOI=10.1007/bf00364432;
RA   Lock C.B., So A.K., Welsh K.I., Parkes J.D., Trowsdale J.;
RT   "MHC class II sequences of an HLA-DR2 narcoleptic.";
RL   Immunogenetics 27:449-455(1988).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:AAA59791.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-28.
RX   PubMed=2001975; DOI=10.1016/0198-8859(91)90069-l;
RA   Demopulos J.T., Hodge T.W., Wooten V., Acton R.T.;
RT   "A novel DRB1 allele in DR2-positive American blacks.";
RL   Hum. Immunol. 30:41-44(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB5*01:01).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:CAI18079.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE DRB5*01:01).
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7] {ECO:0000305, ECO:0000312|EMBL:AAH09234.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE DRB5*01:01).
RC   TISSUE=B-cell {ECO:0000312|EMBL:AAH09234.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 28-140 (ALLELE DRB5*01:04), AND NUCLEOTIDE
RP   SEQUENCE [GENOMIC DNA] OF 35-119 (ALLELE DRB5*02:04).
RC   TISSUE=Blood;
RX   PubMed=9162096; DOI=10.1007/s002510050248;
RA   Robbins F., Hurley C.K., Tang T., Yao H., Lin Y.S., Wade J., Goeken N.,
RA   Hartzman R.J.;
RT   "Diversity associated with the second expressed HLA-DRB locus in the human
RT   population.";
RL   Immunogenetics 46:104-110(1997).
RN   [9] {ECO:0000312|EMBL:AAA36276.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266 (ALLELES DRB5*01:01 AND DRB5*01:02).
RX   PubMed=2885840; DOI=10.1073/pnas.84.13.4591;
RA   Lee B.S.M., Rust N.A., McMichael A.J., McDevitt H.O.;
RT   "HLA-DR2 subtypes form an additional supertypic family of DR beta
RT   alleles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:4591-4595(1987).
RN   [10] {ECO:0000305, ECO:0000312|EMBL:AAA59818.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 30-266, AND VARIANT ALA-154.
RX   PubMed=3476943; DOI=10.1073/pnas.84.17.6234;
RA   Bell J.I., Denney D. Jr., Foster L., Belt T.K., Todd J.A., McDevitt H.O.;
RT   "Allelic variation in the DR subregion of the human major
RT   histocompatibility complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6234-6238(1987).
RN   [11] {ECO:0000312|PIR:B28756}
RP   PROTEIN SEQUENCE OF 30-148 AND 158-178.
RX   PubMed=6576979; DOI=10.1515/bchm2.1983.364.1.749;
RA   Goetz H., Kratzin H., Thinnes F.P., Yang C.-Y., Kruse T., Pauly E.,
RA   Koelbel S., Egert G., Wernet P., Hilschmann N.;
RT   "Primary structure of human class II histocompatibility antigens 3rd
RT   communication. Amino acid sequence comparison between DR and DC subclass
RT   antigens derived from a lymphoblastoid B cell line homozygous at the HLA
RT   loci (HLA-A3,3; B7,7; Dw2,2; DR2,2: MT1,1; Dc1,1: MB1,1).";
RL   Hoppe-Seyler's Z. Physiol. Chem. 364:749-755(1983).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 34-122 (ALLELE DRB5*01:05).
RX   PubMed=8773325; DOI=10.1111/j.1399-0039.1996.tb02563.x;
RA   Poli F., Bianchi P., Crespiatico L., Terragna C., van den Berg-Loonen E.,
RA   Sirchia G.;
RT   "Characterization of a new HLA-DRB5 allele (DRB5*0105) by PCR-SSP and
RT   direct sequencing.";
RL   Tissue Antigens 47:338-340(1996).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-217 (ALLELE DRB5*01:14).
RC   TISSUE=Blood;
RA   Anholts J.D.H.;
RT   "New sequences found during routine HLA typing.";
RL   Submitted (JUL-2009) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*01:06).
RX   PubMed=9226128; DOI=10.1111/j.1365-2370.1997.00267.x;
RA   Kervaire B., Tiercy J.;
RT   "Sequence of a new HLA-DR allele, DRB5*0106.";
RL   Eur. J. Immunogenet. 24:225-228(1997).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*01:03).
RC   TISSUE=Blood;
RA   Hurley C.K.;
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*02:05).
RA   Carter V., Day S., Dunn P.;
RT   "Identification of a new DRB5*02 variant allele by PCR-SSP and SBT.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*01:11).
RA   Greville W.D., Chapman G., Hogbin J.-P., Velickovic Z.;
RT   "Novel HLA-DRB5 allele found by sequence based typing.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*01:12).
RX   PubMed=14617041; DOI=10.1046/j.1399-0039.2003.00124.x;
RA   Atkinson D.C., Jobson S.E., Dunn P.P., Briggs D.C.;
RT   "Identification of a new HLA-DRB5 allele, DRB5*0112, by routine PCR-SSP.";
RL   Tissue Antigens 62:554-555(2003).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-123 (ALLELE DRB5*01:13).
RX   PubMed=16671952; DOI=10.1111/j.1399-0039.2006.00588.x;
RA   Garino E., Berrino M., Bertinetto F., Caropreso P., Chidichimo R.,
RA   Dametto E., Fasano M.E., Frisaldi E., Mazzola G., Tondat F., Boccadoro M.,
RA   Bruno B., Amoroso A.;
RT   "Identification of a new allele, HLA-DRB5*0113, through three different
RT   molecular biology techniques.";
RL   Tissue Antigens 67:427-429(2006).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB5*01:07).
RX   PubMed=9458128; DOI=10.1111/j.1399-0039.1997.tb02933.x;
RA   Buyse I.M., Couture C., Hashemi-Tavoularis S.;
RT   "Identification of novel DRB1*11 (DRB1*11013, DRB1*1129), DRB1*08
RT   (DRB1*0816) and DRB5* (DRB5*0107) alleles.";
RL   Tissue Antigens 50:678-681(1997).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 35-115 (ALLELE DRB5*01:09).
RX   PubMed=9694360; DOI=10.1111/j.1399-0039.1998.tb03010.x;
RA   Buyse I.M., Ouellet S., Hashemi-Tavoularis S.;
RT   "Identification of novel DRB1*13 (DRB1*1333), DRB1*04 (DRB1*0426) and DRB5*
RT   (DRB5*0109) alleles.";
RL   Tissue Antigens 51:658-662(1998).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 36-119 (ALLELE DRB5*02:03).
RX   PubMed=1471145; DOI=10.1111/j.1399-0039.1992.tb02047.x;
RA   Grooms A., Dunckley H., Gao X., Serjeantson S.W.;
RT   "DRB5*HK: a new HLA-DRB5 allele in Cantonese.";
RL   Tissue Antigens 40:210-211(1992).
RN   [23]
RP   REVIEW.
RX   PubMed=8598037; DOI=10.1016/s0092-8674(00)81025-9;
RA   Cresswell P.;
RT   "Invariant chain structure and MHC class II function.";
RL   Cell 84:505-507(1996).
RN   [24]
RP   REVIEW.
RX   PubMed=11684289; DOI=10.1016/s0161-5890(01)00069-4;
RA   Villadangos J.A.;
RT   "Presentation of antigens by MHC class II molecules: getting the most out
RT   of them.";
RL   Mol. Immunol. 38:329-346(2001).
RN   [25]
RP   REVIEW.
RX   PubMed=17241953; DOI=10.1016/j.immuni.2007.01.005;
RA   Menendez-Benito V., Neefjes J.;
RT   "Autophagy in MHC class II presentation: sampling from within.";
RL   Immunity 26:1-3(2007).
RN   [26]
RP   REVIEW.
RX   PubMed=18046453; DOI=10.1038/sj.emboj.7601945;
RA   Rocha N., Neefjes J.;
RT   "MHC class II molecules on the move for successful antigen presentation.";
RL   EMBO J. 27:1-5(2008).
RN   [27]
RP   UBIQUITINATION BY MARCH1, AND SUBCELLULAR LOCATION.
RX   PubMed=18305173; DOI=10.1073/pnas.0708874105;
RA   De Gassart A., Camosseto V., Thibodeau J., Ceppi M., Catalan N., Pierre P.,
RA   Gatti E.;
RT   "MHC class II stabilization at the surface of human dendritic cells is the
RT   result of maturation-dependent MARCH I down-regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3491-3496(2008).
RN   [28]
RP   REVIEW.
RX   PubMed=19092054; DOI=10.1242/jcs.035089;
RA   Berger A.C., Roche P.A.;
RT   "MHC class II transport at a glance.";
RL   J. Cell Sci. 122:1-4(2009).
RN   [29]
RP   REVIEW.
RX   PubMed=19533806; DOI=10.3748/wjg.15.2855;
RA   Beswick E.J., Reyes V.E.;
RT   "CD74 in antigen presentation, inflammation, and cancers of the
RT   gastrointestinal tract.";
RL   World J. Gastroenterol. 15:2855-2861(2009).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-48.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [32] {ECO:0000305}
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 30-219 OF HLA-DRA/HLA-DRB5
RP   HETERODIMER IN COMPLEX WITH MBP PEPTIDE, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=11080454; DOI=10.1006/jmbi.2000.4198;
RA   Li Y., Li H., Martin R., Mariuzza R.A.;
RT   "Structural basis for the binding of an immunodominant peptide from myelin
RT   basic protein in different registers by two HLA-DR2 proteins.";
RL   J. Mol. Biol. 304:177-188(2000).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 30-219 OF HLA-DRA/HLA-DRB5
RP   HETERODIMER IN COMPLEX WITH MPB PEPTIDE AND STREPTOCOCCUS PYOGENES
RP   SPEC PEPTIDE, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=11163233; DOI=10.1016/s1074-7613(01)00092-9;
RA   Li Y., Li H., Dimasi N., McCormick J.K., Martin R., Schuck P.,
RA   Schlievert P.M., Mariuzza R.A.;
RT   "Crystal structure of a superantigen bound to the high-affinity, zinc-
RT   dependent site on MHC class II.";
RL   Immunity 14:93-104(2001).
RN   [34] {ECO:0000312|PDB:1H15}
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 30-219 OF HLA-DRA/HLA-DRB5
RP   HETERODIMER IN COMPLEX EPSTEIN-BARR VIRUS BALF5 PEPTIDE, SUBUNIT, AND
RP   DISULFIDE BONDS.
RX   PubMed=12244309; DOI=10.1038/ni835;
RA   Lang H.L.E., Jacobsen H., Ikemizu S., Andersson C., Harlos K., Madsen L.,
RA   Hjorth P., Sondergaard L., Svejgaard A., Wucherpfennig K., Stuart D.I.,
RA   Bell J.I., Jones E.Y., Fugger L.;
RT   "A functional and structural basis for TCR cross-reactivity in multiple
RT   sclerosis.";
RL   Nat. Immunol. 3:940-943(2002).
RN   [35] {ECO:0000305}
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 30-221 OF HLA-DRA/HLA-DRB5
RP   HETERODIMER IN COMPLEX WITH MBP PEPTIDE AND TRAC, SUBUNIT, AND DISULFIDE
RP   BONDS.
RX   PubMed=16079912; DOI=10.1038/sj.emboj.7600771;
RA   Li Y., Huang Y., Lue J., Quandt J.A., Martin R., Mariuzza R.A.;
RT   "Structure of a human autoimmune TCR bound to a myelin basic protein self-
RT   peptide and a multiple sclerosis-associated MHC class II molecule.";
RL   EMBO J. 24:2968-2979(2005).
CC   -!- FUNCTION: Binds peptides derived from antigens that access the
CC       endocytic route of antigen presenting cells (APC) and presents them on
CC       the cell surface for recognition by the CD4 T-cells. The peptide
CC       binding cleft accommodates peptides of 10-30 residues. The peptides
CC       presented by MHC class II molecules are generated mostly by degradation
CC       of proteins that access the endocytic route, where they are processed
CC       by lysosomal proteases and other hydrolases. Exogenous antigens that
CC       have been endocytosed by the APC are thus readily available for
CC       presentation via MHC II molecules, and for this reason this antigen
CC       presentation pathway is usually referred to as exogenous. As membrane
CC       proteins on their way to degradation in lysosomes as part of their
CC       normal turn-over are also contained in the endosomal/lysosomal
CC       compartments, exogenous antigens must compete with those derived from
CC       endogenous components. Autophagy is also a source of endogenous
CC       peptides, autophagosomes constitutively fuse with MHC class II loading
CC       compartments. In addition to APCs, other cells of the gastrointestinal
CC       tract, such as epithelial cells, express MHC class II molecules and
CC       CD74 and act as APCs, which is an unusual trait of the GI tract. To
CC       produce a MHC class II molecule that presents an antigen, three MHC
CC       class II molecules (heterodimers of an alpha and a beta chain)
CC       associate with a CD74 trimer in the ER to form a heterononamer. Soon
CC       after the entry of this complex into the endosomal/lysosomal system
CC       where antigen processing occurs, CD74 undergoes a sequential
CC       degradation by various proteases, including CTSS and CTSL, leaving a
CC       small fragment termed CLIP (class-II-associated invariant chain
CC       peptide). The removal of CLIP is facilitated by HLA-DM via direct
CC       binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM
CC       stabilizes MHC class II molecules until primary high affinity antigenic
CC       peptides are bound. The MHC II molecule bound to a peptide is then
CC       transported to the cell membrane surface. In B-cells, the interaction
CC       between HLA-DM and MHC class II molecules is regulated by HLA-DO.
CC       Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal
CC       microenvironment has been implicated in the regulation of antigen
CC       loading into MHC II molecules, increased acidification produces
CC       increased proteolysis and efficient peptide loading.
CC   -!- SUBUNIT: Heterodimer of an alpha and a beta subunit; also referred as
CC       MHC class II molecule. In the endoplasmic reticulum (ER) it forms a
CC       heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also
CC       known as invariant chain or HLA class II histocompatibility antigen
CC       gamma chain). In the endosomal/lysosomal system; CD74 undergoes
CC       sequential degradation by various proteases; leaving a small fragment
CC       termed CLIP on each MHC class II molecule. MHC class II molecule
CC       interacts with HLA_DM, and HLA_DO in B-cells, in order to release CLIP
CC       and facilitate the binding of antigenic peptides.
CC       {ECO:0000269|PubMed:11080454, ECO:0000269|PubMed:11163233,
CC       ECO:0000269|PubMed:12244309, ECO:0000269|PubMed:16079912}.
CC   -!- INTERACTION:
CC       Q30154; O14757: CHEK1; NbExp=2; IntAct=EBI-2798348, EBI-974488;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18305173};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:18305173,
CC       ECO:0000305}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:18305173}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:18305173, ECO:0000305}. Golgi apparatus, trans-
CC       Golgi network membrane {ECO:0000269|PubMed:18305173}; Single-pass type
CC       I membrane protein {ECO:0000269|PubMed:18305173, ECO:0000305}. Endosome
CC       membrane {ECO:0000269|PubMed:18305173}; Single-pass type I membrane
CC       protein {ECO:0000269|PubMed:18305173, ECO:0000305}. Lysosome membrane
CC       {ECO:0000269|PubMed:18305173}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:18305173, ECO:0000305}. Late endosome membrane
CC       {ECO:0000269|PubMed:18305173}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:18305173, ECO:0000305}. Note=The MHC class II
CC       complex transits through a number of intracellular compartments in the
CC       endocytic pathway until it reaches the cell membrane for antigen
CC       presentation.
CC   -!- PTM: Ubiquitinated by MARCH1 and MARCH8 at Lys-254 leading to down-
CC       regulation of MHC class II. {ECO:0000305|PubMed:18305173}.
CC   -!- POLYMORPHISM: The following alleles of DRB5 are known: DRB5*01:01,
CC       DRB5*01:02, DRB5*01:03, DRB5*01:04, DRB5*01:05, DRB5*01:06, DRB5*01:07,
CC       DRB5*01:09, DRB5*01:11, DRB5*01:12 DRB5*01:13, DRB5*01:14, DRB5*02:02,
CC       DRB5*02:03, DRB5*02:04, DRB5*02:05. The sequence shown is that of
CC       DRB5*01:01.
CC   -!- SIMILARITY: Belongs to the MHC class II family. {ECO:0000255}.
CC   -!- CAUTION: HLA-DRB3, HLA-DRB4 and HLA-DRB5 may represent a unique gene.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M20429; AAA59822.1; -; mRNA.
DR   EMBL; M35159; AAA59791.1; -; Genomic_DNA.
DR   EMBL; AL713966; CAI18079.1; -; Genomic_DNA.
DR   EMBL; AK314834; BAG37353.1; -; mRNA.
DR   EMBL; BC009234; AAH09234.1; -; mRNA.
DR   EMBL; U31770; AAB63983.1; -; mRNA.
DR   EMBL; U59685; AAB52229.1; -; Genomic_DNA.
DR   EMBL; M16954; AAA36276.1; -; mRNA.
DR   EMBL; M16955; AAA36277.1; -; mRNA.
DR   EMBL; M17377; AAA59818.1; -; mRNA.
DR   EMBL; X87210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; FN430425; CAZ86696.1; -; Genomic_DNA.
DR   EMBL; Z83201; CAB05668.1; -; Genomic_DNA.
DR   EMBL; AF122887; AAD31766.1; -; Genomic_DNA.
DR   EMBL; AJ271159; CAB71144.1; -; Genomic_DNA.
DR   EMBL; AY141137; AAN28924.1; -; Genomic_DNA.
DR   EMBL; AJ427352; CAD20460.1; -; Genomic_DNA.
DR   EMBL; AY457037; AAR20446.2; -; Genomic_DNA.
DR   EMBL; Y09342; CAA70524.1; -; Genomic_DNA.
DR   EMBL; Y13727; CAA74055.1; -; Genomic_DNA.
DR   EMBL; M91001; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS4751.1; -.
DR   PIR; B27060; B27060.
DR   PIR; B28043; B28043.
DR   PIR; B28756; B28756.
DR   PIR; C32526; C32526.
DR   PIR; D25239; D25239.
DR   PIR; I68733; I68733.
DR   PIR; PT0169; PT0169.
DR   PIR; PT0170; PT0170.
DR   PIR; PT0171; PT0171.
DR   RefSeq; NP_002116.2; NM_002125.3.
DR   PDB; 1FV1; X-ray; 1.90 A; B/E=30-219.
DR   PDB; 1H15; X-ray; 3.10 A; B/E=30-219.
DR   PDB; 1HQR; X-ray; 3.20 A; B=30-219.
DR   PDB; 1ZGL; X-ray; 2.80 A; B/E/H/K=30-221.
DR   PDBsum; 1FV1; -.
DR   PDBsum; 1H15; -.
DR   PDBsum; 1HQR; -.
DR   PDBsum; 1ZGL; -.
DR   AlphaFoldDB; Q30154; -.
DR   SMR; Q30154; -.
DR   BioGRID; 109372; 39.
DR   FunCoup; Q30154; 440.
DR   IntAct; Q30154; 24.
DR   MINT; Q30154; -.
DR   STRING; 9606.ENSP00000364114; -.
DR   ChEMBL; CHEMBL3988561; -.
DR   DrugBank; DB05121; 1D09C3.
DR   DrugBank; DB11294; Coccidioides immitis spherule.
DR   GlyConnect; 1378; 2 N-Linked glycans (1 site).
DR   GlyCosmos; Q30154; 1 site, 2 glycans.
DR   GlyGen; Q30154; 1 site, 40 N-linked glycans (1 site).
DR   iPTMnet; Q30154; -.
DR   PhosphoSitePlus; Q30154; -.
DR   SwissPalm; Q30154; -.
DR   BioMuta; HLA-DRB5; -.
DR   DMDM; 74754558; -.
DR   jPOST; Q30154; -.
DR   MassIVE; Q30154; -.
DR   PaxDb; 9606-ENSP00000364114; -.
DR   PeptideAtlas; Q30154; -.
DR   ProteomicsDB; 61556; -.
DR   Pumba; Q30154; -.
DR   Antibodypedia; 13708; 207 antibodies from 23 providers.
DR   DNASU; 3127; -.
DR   Ensembl; ENST00000374975.4; ENSP00000364114.3; ENSG00000198502.8.
DR   GeneID; 3127; -.
DR   KEGG; hsa:3127; -.
DR   MANE-Select; ENST00000374975.4; ENSP00000364114.3; NM_002125.4; NP_002116.2.
DR   UCSC; uc003obj.4; human.
DR   AGR; HGNC:4953; -.
DR   ClinPGx; PA35076; -.
DR   CTD; 3127; -.
DR   DisGeNET; 3127; -.
DR   GeneCards; HLA-DRB5; -.
DR   HGNC; HGNC:4953; HLA-DRB5.
DR   HPA; ENSG00000198502; Tissue enhanced (lung, lymphoid tissue).
DR   MalaCards; HLA-DRB5; -.
DR   MIM; 604776; gene.
DR   OpenTargets; ENSG00000198502; -.
DR   VEuPathDB; HostDB:ENSG00000198502; -.
DR   eggNOG; ENOG502RYBQ; Eukaryota.
DR   GeneTree; ENSGT00940000154993; -.
DR   HOGENOM; CLU_047501_13_1_1; -.
DR   InParanoid; Q30154; -.
DR   OMA; ANAFFGY; -.
DR   PAN-GO; Q30154; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; Q30154; -.
DR   PathwayCommons; Q30154; -.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-202427; Phosphorylation of CD3 and TCR zeta chains.
DR   Reactome; R-HSA-202430; Translocation of ZAP-70 to Immunological synapse.
DR   Reactome; R-HSA-202433; Generation of second messenger molecules.
DR   Reactome; R-HSA-2132295; MHC class II antigen presentation.
DR   Reactome; R-HSA-389948; Co-inhibition by PD-1.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   SignaLink; Q30154; -.
DR   SIGNOR; Q30154; -.
DR   Agora; ENSG00000198502; -.
DR   BioGRID-ORCS; 3127; 11 hits in 1057 CRISPR screens.
DR   ChiTaRS; HLA-DRB5; human.
DR   EvolutionaryTrace; Q30154; -.
DR   GeneWiki; HLA-DRB5; -.
DR   GenomeRNAi; 3127; -.
DR   Pharos; Q30154; Tbio.
DR   PRO; PR:Q30154; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q30154; protein.
DR   Bgee; ENSG00000198502; Expressed in granulocyte and 101 other cell types or tissues.
DR   ExpressionAtlas; Q30154; baseline and differential.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0012507; C:ER to Golgi transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0031902; C:late endosome membrane; IDA:UniProtKB.
DR   GO; GO:0098553; C:lumenal side of endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0042613; C:MHC class II protein complex; ISS:CAFA.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; TAS:Reactome.
DR   GO; GO:0030658; C:transport vesicle membrane; TAS:Reactome.
DR   GO; GO:0023026; F:MHC class II protein complex binding; IBA:GO_Central.
DR   GO; GO:0042605; F:peptide antigen binding; ISS:CAFA.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0019886; P:antigen processing and presentation of exogenous peptide antigen via MHC class II; IBA:GO_Central.
DR   GO; GO:0002503; P:peptide antigen assembly with MHC class II protein complex; IBA:GO_Central.
DR   GO; GO:0050778; P:positive regulation of immune response; IBA:GO_Central.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IBA:GO_Central.
DR   CDD; cd21000; IgC1_MHC_II_beta_HLA-DR; 1.
DR   FunFam; 2.60.40.10:FF:000116; HLA class II histocompatibility antigen, DRB1-1 beta chain; 1.
DR   FunFam; 3.10.320.10:FF:000001; HLA class II histocompatibility antigen, DRB1-1 beta chain; 1.
DR   Gene3D; 3.10.320.10; Class II Histocompatibility Antigen, M Beta Chain, Chain B, domain 1; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003006; Ig/MHC_CS.
DR   InterPro; IPR003597; Ig_C1-set.
DR   InterPro; IPR050160; MHC/Immunoglobulin.
DR   InterPro; IPR011162; MHC_I/II-like_Ag-recog.
DR   InterPro; IPR014745; MHC_II_a/b_N.
DR   InterPro; IPR000353; MHC_II_b_N.
DR   PANTHER; PTHR19944:SF97; HLA CLASS II HISTOCOMPATIBILITY ANTIGEN, DR BETA 5 CHAIN; 1.
DR   PANTHER; PTHR19944; MHC CLASS II-RELATED; 1.
DR   Pfam; PF07654; C1-set; 1.
DR   Pfam; PF00969; MHC_II_beta; 1.
DR   SMART; SM00407; IGc1; 1.
DR   SMART; SM00921; MHC_II_beta; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   SUPFAM; SSF54452; MHC antigen-recognition domain; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00290; IG_MHC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Golgi apparatus; Immunity; Lysosome; Membrane; MHC II;
KW   Proteomics identification; Reference proteome; Signal; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000269|PubMed:6576979"
FT   CHAIN           30..266
FT                   /note="HLA class II histocompatibility antigen, DR beta 5
FT                   chain"
FT                   /id="PRO_5000143106"
FT   TOPO_DOM        30..227
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        228..248
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        249..266
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          126..214
FT                   /note="Ig-like C1-type"
FT                   /evidence="ECO:0000255"
FT   REGION          30..124
FT                   /note="Beta-1"
FT                   /evidence="ECO:0000255"
FT   REGION          125..227
FT                   /note="Beta-2"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        48
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   DISULFID        44..108
FT   DISULFID        146..202
FT   VARIANT         14
FT                   /note="K -> M (in dbSNP:rs1064587)"
FT                   /id="VAR_060951"
FT   VARIANT         14
FT                   /note="K -> Q (in dbSNP:rs701884)"
FT                   /id="VAR_060952"
FT   VARIANT         14
FT                   /note="K -> V (in allele DRB5*02:02; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_060953"
FT   VARIANT         20
FT                   /note="M -> T (in dbSNP:rs17211043)"
FT                   /id="VAR_050355"
FT   VARIANT         28
FT                   /note="L -> S"
FT                   /evidence="ECO:0000269|PubMed:2001975,
FT                   ECO:0000269|PubMed:3099214, ECO:0000269|PubMed:3571980"
FT                   /id="VAR_039871"
FT   VARIANT         33
FT                   /note="R -> Q (in dbSNP:rs1141741)"
FT                   /id="VAR_050356"
FT   VARIANT         35
FT                   /note="R -> C (in allele DRB5*02:02, allele DRB5*02:04 and
FT                   allele DRB5*02:05; dbSNP:rs1136744)"
FT                   /id="VAR_060954"
FT   VARIANT         41
FT                   /note="K -> T (in dbSNP:rs200581589)"
FT                   /id="VAR_050357"
FT   VARIANT         57
FT                   /note="H -> Q (in dbSNP:rs202185589)"
FT                   /id="VAR_060955"
FT   VARIANT         59
FT                   /note="D -> G (in allele DRB5*01:02, allele DRB5*01:03,
FT                   allele DRB5*02:02, allele DRB5*02:03, allele DRB5*02:04 and
FT                   allele DRB5*02:05; dbSNP:rs41546317)"
FT                   /id="VAR_060956"
FT   VARIANT         62
FT                   /note="N -> H (in dbSNP:rs1059576)"
FT                   /id="VAR_050358"
FT   VARIANT         66
FT                   /note="D -> N (in allele DRB5*01:02, allele DRB5*01:03,
FT                   allele DRB5*02:02, allele DRB5*02:03, allele DRB5*02:04 and
FT                   allele DRB5*02:05; dbSNP:rs707956)"
FT                   /id="VAR_060958"
FT   VARIANT         66
FT                   /note="D -> Y (in allele DRB5*01:14; dbSNP:rs707956)"
FT                   /id="VAR_060959"
FT   VARIANT         67
FT                   /note="L -> V (in allele DRB5*01:02, allele DRB5*01:03,
FT                   allele DRB5*01:05, allele DRB5*01:14, allele DRB5*02:02,
FT                   allele DRB5*02:03, allele DRB5*02:04 and allele DRB5*02:05;
FT                   dbSNP:rs1059580)"
FT                   /id="VAR_060960"
FT   VARIANT         87
FT                   /note="A -> E (in allele DRB5*01:13)"
FT                   /id="VAR_060961"
FT   VARIANT         89
FT                   /note="Y -> S (in allele DRB5*01:12; dbSNP:rs41541218)"
FT                   /id="VAR_060962"
FT   VARIANT         96
FT                   /note="F -> I (in allele DRB5*01:06, allele DRB5*01:07,
FT                   allele DRB5*01:11, allele DRB5*02:02 and allele DRB5*02:03;
FT                   dbSNP:rs696318)"
FT                   /id="VAR_060964"
FT   VARIANT         96
FT                   /note="F -> L (in allele DRB5*02:05; dbSNP:rs696318)"
FT                   /id="VAR_060963"
FT   VARIANT         99
FT                   /note="D -> E (in dbSNP:rs41559913)"
FT                   /id="VAR_060965"
FT   VARIANT         99
FT                   /note="D -> G (in dbSNP:rs41545413)"
FT                   /id="VAR_060966"
FT   VARIANT         99
FT                   /note="D -> H (in dbSNP:rs41547217)"
FT                   /id="VAR_060967"
FT   VARIANT         99
FT                   /note="D -> N (in allele DRB5*01:09; dbSNP:rs41547217)"
FT                   /id="VAR_060968"
FT   VARIANT         99
FT                   /note="D -> Q (in allele DRB5*01:06, allele DRB5*01:11,
FT                   allele DRB5*02:02, allele DRB5*02:03, allele DRB5*02:04 and
FT                   allele DRB5*02:05; requires 2 nucleotide substitutions)"
FT                   /id="VAR_060969"
FT   VARIANT         99
FT                   /note="D -> R (in allele DRB5*01:12; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_060970"
FT   VARIANT         100
FT                   /note="R -> A (in allele DRB5*01:06, allele DRB5*01:11,
FT                   allele DRB5*02:02, allele DRB5*02:03 and allele DRB5*02:04;
FT                   requires 2 nucleotide substitutions)"
FT                   /id="VAR_060971"
FT   VARIANT         100
FT                   /note="R -> G (in dbSNP:rs41551116)"
FT                   /id="VAR_060972"
FT   VARIANT         100
FT                   /note="R -> T (in allele DRB5*01:03; dbSNP:rs41544215)"
FT                   /id="VAR_060973"
FT   VARIANT         103
FT                   /note="A -> E (in allele DRB5*01:12; dbSNP:rs1059598)"
FT                   /id="VAR_060974"
FT   VARIANT         103
FT                   /note="A -> L (in allele DRB5*01:04; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_060975"
FT   VARIANT         106
FT                   /note="T -> N (in dbSNP:rs115817940)"
FT                   /id="VAR_050359"
FT   VARIANT         107
FT                   /note="Y -> V (in allele DRB5*01:12; requires 2 nucleotide
FT                   substitutions)"
FT                   /id="VAR_060976"
FT   VARIANT         114
FT                   /note="V -> A (in allele DRB5*01:06, allele DRB5*02:02,
FT                   allele DRB5*02:04 and allele DRB5*02:05; dbSNP:rs1136778)"
FT                   /id="VAR_060977"
FT   VARIANT         115
FT                   /note="G -> V (in allele DRB5*01:06, allele DRB5*02:02,
FT                   allele DRB5*02:04 and allele DRB5*02:05; dbSNP:rs41556512)"
FT                   /id="VAR_060978"
FT   VARIANT         154
FT                   /note="G -> A (in dbSNP:rs113395425)"
FT                   /evidence="ECO:0000269|PubMed:3099214,
FT                   ECO:0000269|PubMed:3476943"
FT                   /id="VAR_039872"
FT   VARIANT         164
FT                   /note="S -> G (in allele DRB5*02:02; dbSNP:rs1059633)"
FT                   /id="VAR_060979"
FT   VARIANT         186
FT                   /note="T -> I (in allele DRB5*02:02; dbSNP:rs41559420)"
FT                   /id="VAR_060980"
FT   VARIANT         232
FT                   /note="V -> I (in allele DRB5*02:02; dbSNP:rs41553512)"
FT                   /id="VAR_060981"
FT   CONFLICT        139
FT                   /note="Q -> E (in Ref. 11; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   STRAND          36..47
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   TURN            48..51
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          52..61
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          64..70
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   TURN            71..73
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          75..80
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           81..83
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           84..91
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           94..101
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           103..106
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           108..115
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   HELIX           116..118
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   TURN            119..121
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          127..132
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          137..154
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          157..166
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          169..173
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          180..182
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          184..192
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          199..205
FT                   /evidence="ECO:0007829|PDB:1FV1"
FT   STRAND          213..218
FT                   /evidence="ECO:0007829|PDB:1FV1"
SQ   SEQUENCE   266 AA;  30056 MW;  0D4335BAEEA6AF22 CRC64;
     MVCLKLPGGS YMAKLTVTLM VLSSPLALAG DTRPRFLQQD KYECHFFNGT ERVRFLHRDI
     YNQEEDLRFD SDVGEYRAVT ELGRPDAEYW NSQKDFLEDR RAAVDTYCRH NYGVGESFTV
     QRRVEPKVTV YPARTQTLQH HNLLVCSVNG FYPGSIEVRW FRNSQEEKAG VVSTGLIQNG
     DWTFQTLVML ETVPRSGEVY TCQVEHPSVT SPLTVEWRAQ SESAQSKMLS GVGGFVLGLL
     FLGAGLFIYF KNQKGHSGLH PTGLVS
//
